Firm News

Julie Cohen
Director of Marketing and Communications
212.701.3614
jcohen@cahill.com

Valeant Pharmaceuticals Completes Bond Offering

Date: 02/08/11

Cahill represented the initial purchasers in a Rule 144A/Reg S Offering of $650 million of 6.750% Senior Notes due 2021 by Valeant Pharmaceuticals International. Valeant intends to use the net proceeds from the offering of the Notes to finance acquisitions and for general corporate purposes.

Julie Cohen
Director of Marketing and Communications
212.701.3614
jcohen@cahill.com